QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-trevena-to-neutral-maintains-5-price-target

HC Wainwright & Co. analyst Douglas Tsao downgrades Trevena (OTC:TRVN) from Buy to Neutral and maintains $5 price target.

 trevena-q3-2024-gaap-eps-579-beats-738-estimate-sales-28300-down-from-18000k-yoy

Trevena (NASDAQ:TRVN) reported quarterly losses of $(5.79) per share which beat the analyst consensus estimate of $(7.38) by 21...

 why-trevena-trvn-stock-is-down-43-today

Trevena shares are trading lower by 47% during Monday's session. The company announced it received a Nasdaq delisting notif...

Core News & Articles

SRRK: 382% | Scholar Rock Holding shares are trading higher after the company announced topline results from the Phase 3 SAPPHI...

 trevena-receives-receipt-of-nasdaq-delisting-notification

Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines fo...

 reported-earlier-trevena-q2-eps-023-beats-040-estimate-sales-32500k-down-from-302m-yoy

Trevena (NASDAQ:TRVN) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.40) by 42...

 trevena-announces-1-for-25-reverse-stock-split-effective-tuesday-august-13-2024

Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION